文献速递血栓与止血

PRN1008/PRN473选择性抑制Btk阻断人CLEC-2,且PRN473减少小鼠静脉血栓形成

Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice.
PubMed 文献 · Blood Adv · 2024-01-01

研究评估选择性Btk抑制剂PRN1008(rilzabrutinib)和PRN473对CLEC-2及糖蛋白VI介导的血小板信号与功能的影响,使用健康供者和XLA血小板及小鼠模型。两者强效抑制CLEC-2介导的血小板活化,未见SFK脱靶抑制;PRN473减少沙门菌感染后podoplanin阳性血管中血栓数量及静脉狭窄后IVC血栓形成。

要点

  • PRN1008和PRN473强效抑制rhodocytin诱导的CLEC-2介导血小板活化。
  • 未观察到对Src家族激酶的脱靶抑制。
  • PRN473减少小鼠沙门菌感染后podoplanin阳性血管血栓数及IVC狭窄后血栓形成。

核心结论

  • PRN1008和PRN473强效抑制人血小板CLEC-2,PRN473在体内模型中减少血栓形成。
  • 结合无SFK脱靶抑制及rilzabrutinib治疗免疫性血小板减少症患者无出血报告,提示Btk抑制为有前景的抗血栓策略。

研究设计与样本

  • 使用健康供者和X连锁无丙种球蛋白血症(XLA)患者血小板评估选择性Btk抑制剂PRN1008和PRN473对CLEC-2及糖蛋白VI介导的血小板信号与功能的影响。
  • 采用下腔静脉(IVC)狭窄和沙门菌感染小鼠模型评估PRN473的体内抗血栓作用。

主要发现

  • PRN1008和PRN473强效抑制rhodocytin诱导的CLEC-2介导血小板活化。
  • 未观察到对Src家族激酶(SFK)的脱靶抑制。
  • PRN1008处理Btk缺陷血小板导致聚集和酪氨酸磷酸化轻微额外抑制,可能反映对Tec的抑制。
  • 未观察到对G蛋白偶联受体介导血小板功能的影响。
  • PRN473显著减少沙门菌感染后podoplanin阳性血管中血栓数量及静脉狭窄后IVC血栓形成。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Platelet C-type lectin-like receptor 2 (CLEC-2) is a hem-immunoreceptor tyrosine-based activation motif-containing receptor that has a critical role in venous thrombosis but minimal involvement in hemostasis. CLEC-2 can be blocked by Btk inhibitors. Treatment with ibrutinib is associated with increased bleeding due to off-target inhibition of Src family kinases (SFKs). Patients with X-linked agammaglobulinemia (XLA) who lack Btk, however, do not bleed, suggesting selective Btk inhibition as a viable antithrombotic strategy. We assessed the effects of selective Btk inhibitors PRN1008 (rilzabrutinib) and PRN473 on platelet signaling and function mediated by CLEC-2 and glycoprotein-VI. We used healthy donors and XLA platelets to determine off-target inhibitor effects. Inferior vena cava (IVC) stenosis and Salmonella infection mouse models were used to assess antithrombotic effects of PRN473 in vivo. PRN1008 and PRN473 potently inhibited CLEC-2-mediated platelet activation to rhodocytin. No off-target inhibition of SFKs was seen. PRN1008 treatment of Btk-deficient platelets resulted in minor additional inhibition of aggregation and tyrosine phosphorylation, likely reflecting inhibition of Tec. No effect on G protein-coupled receptor-mediated platelet function was observed. PRN473 significantly reduced the number of thrombi in podoplanin-positive vessels after Salmonella infection and the presence of IVC thrombosis after vein stenosis. The potent inhibition of human platelet CLEC-2 and reduced thrombosis in in vivo models, together with the lack of off-target SFK inhibition and absence of bleeding reported in rilzabrutinib-treated patients with immune thrombocytopenia, suggest Btk inhibition as a promising antithrombotic strategy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Smith CW, Campos J, Brown HC, et al. Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice. Blood Adv. 2024. PMID: 38968150. doi:10.1182/bloodadvances.2024012713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。